Applied DNA Abstracts Selected for Poster Presentations Showcasing LineaDNA and LineaIVT Platforms at Upcoming mRNA and CAR T Industry Conferences
Applied DNA Sciences (NASDAQ:APDN) announced its participation in two major industry conferences where it will present posters highlighting its nucleic acid production solutions. The company will showcase its technology at the 4th Annual mRNA Process Development and CMC Summit in Boston (September 23-25), featuring a poster on fast-tracking mRNA medicines using their synthetic DNA platform.
Additionally, at the 10th Annual CAR-TCR Summit (September 23-26), the company will present findings on CD123-specific CAR-T Cells produced using their LineaDNA™-based piggyBac Transposon System, including Phase I Clinical Trial initiation for AML patients. The company will also feature its IVT Discovery Kit for evaluating and optimizing in vitro transcription.
Applied DNA Sciences (NASDAQ:APDN) ha annunciato la partecipazione a due importanti conferenze di settore, dove presenterà poster che evidenziano le sue soluzioni per la produzione di acidi nucleici. L'azienda mostrerà la sua tecnologia al 4th Annual mRNA Process Development and CMC Summit a Boston (23-25 settembre), con un poster su come accelerare i farmaci a base di mRNA utilizzando la loro piattaforma di DNA sintetico.
Inoltre, al 10th Annual CAR-TCR Summit (23-26 settembre), presenterà dati su cellule CAR-T specifiche CD123 prodotte utilizzando il sistema piggyBac Transposon LineaDNA™, incluso l'avvio della sperimentazione di Fase I per pazienti AML. L'azienda presenterà anche il IVT Discovery Kit per valutare e ottimizzare la trascrizione in vitro.
Applied DNA Sciences (NASDAQ:APDN) anunció su participación en dos importantes conferencias de la industria, donde presentará pósteres que destacan sus soluciones para la producción de ácidos nucleicos. La empresa mostrará su tecnología en el 4th Annual mRNA Process Development and CMC Summit en Boston (23-25 de septiembre), con un póster sobre acelerar los fármacos de ARNm utilizando su plataforma de ADN sintético.
Además, en el 10th Annual CAR-TCR Summit (23-26 de septiembre), presentará resultados sobre células CAR-T específicas CD123 producidas mediante su sistema piggyBac Transposon LineaDNA™, incluyendo el inicio de la Fase I de ensayos clínicos para pacientes con AML. La empresa también presentará su IVT Discovery Kit para evaluar y optimizar la transcripción in vitro.
Applied DNA Sciences (NASDAQ:APDN)가 두 개의 주요 업계 학회 참석을 발표했습니다. 이 회사는 핵산 생산 솔루션을 강조하는 포스터를 발표할 예정이며, 보스턴에서 열리는 4th Annual mRNA Process Development and CMC Summit에서 합성 DNA 플랫폼을 사용한 mRNA 약물의 신속 개발에 관한 포스터를 선보입니다(9월 23-25일).
또한 10th Annual CAR-TCR Summit에서(9월 23-26일) LineaDNA™ 기반 piggyBac Transposon System을 사용해 생산한 CD123 특이 CAR-T 세포에 대한 연구 결과를 발표하고 AML 환자를 위한 1상 임상시험 개시도 포함합니다. 회사는 또한 IVT Discovery Kit를 소개하여 in vitro 전사를 평가하고 최적화하는 데 도움을 줍니다.
Applied DNA Sciences (NASDAQ:APDN) a annoncé sa participation à deux grandes conférences industrielles, où elle présentera des posters mettant en avant ses solutions de production d'acides nucléiques. L'entreprise exposera sa technologie lors du 4th Annual mRNA Process Development and CMC Summit à Boston (du 23 au 25 septembre), avec un poster sur l’accélération des médicaments à ARNm en utilisant leur plateforme d’ADN synthétique.
Par ailleurs, lors du 10th Annual CAR-TCR Summit (du 23 au 26 septembre), elle présentera des résultats sur des cellules CAR-T spécifiques CD123 produites via leur système piggyBac Transposon LineaDNA™, y compris le démarrage de l’étude de Phase I pour des patients atteints de LAM. L’entreprise mettra également en avant son IVT Discovery Kit pour évaluer et optimiser la transcription in vitro.
Applied DNA Sciences (NASDAQ:APDN) kündigt seine Teilnahme an zwei wichtigen Branchenkonferenzen an, auf denen Poster zu seinen Lösungen zur Nukleinsäureproduktion vorgestellt werden. Das Unternehmen wird seine Technologie beim 4th Annual mRNA Process Development and CMC Summit in Boston (23.–25. September) präsentieren, mit einem Poster zur beschleunigten Entwicklung von mRNA-Arzneimitteln unter Nutzung ihrer synthetischen DNA-Plattform.
Außerdem wird es beim 10th Annual CAR-TCR Summit (23.–26. September) Ergebnisse zu CD123-spezifischen CAR-T-Zellen präsentieren, die mit ihrem LineaDNA™-basierten piggyBac-Transposon-System hergestellt wurden, einschließlich des Starts der Phase-I-Studie für AML-Patienten. Das Unternehmen wird außerdem sein IVT Discovery Kit vorstellen, um In-vitro-Transkription zu bewerten und zu optimieren.
Applied DNA Sciences (NASDAQ:APDN) أعلنت عن مشاركتها في مؤتمرين صناعيين رئيسيين ستقدم فيهما ملصقات تُبرز حلولها في إنتاج الأحماض النووية. ستعرض الشركة تقنيتها في 4th Annual mRNA Process Development and CMC Summit في بوسطن (23-25 سبتمبر)، مع ملصق يسلط الضوء على تسريع أدوية الـmRNA باستخدام منصة DNA الاصطناعية الخاصة بهم.
وبالإضافة إلى ذلك، في مؤتمر 10th Annual CAR-TCR Summit (23-26 سبتمبر)، ستعرض نتائج حول خلايا CAR-T الخاصة بـCD123 المُنتجة باستخدام نظام piggyBac Transposon LineaDNA™ القائم على LineaDNA، بما في ذلك بدء تجربة المرحلة الأولى لمرضى AML. ستعرض الشركة أيضًا IVT Discovery Kit لتقييم وتحسين النسخ في المختبر.
Applied DNA Sciences（纳斯达克股票代码：APDN）宣布将参与两场重要行业会议，并在会上展示突出其核酸生产解决方案的海报。公司将在第四届年度 mRNA 工艺开发与 CMC 峰会（波士顿，9月23-25日）展示其技术，海报主题为使用其合成 DNA 平台快速推动 mRNA 药物的开发。
此外，在第十届年度 CAR-TCR 峰会（9月23-26日）上，公司将展示使用其 LineaDNA™ 基于 piggyBac 转座子系统生产的 CD123 特异性 CAR-T 细胞的研究结果，其中包括 AML 患者的一期临床试验启动。公司还将展示其 IVT Discovery Kit，用于评估和优化体外转录。
- None.
- None.
Insights
Applied DNA showcasing its nucleic acid platforms at major conferences; CD123 CAR-T cell therapy entering Phase I trials represents meaningful clinical progression.
Applied DNA's upcoming presentations at two major biotechnology conferences highlight significant technical and clinical advances for the company's synthetic DNA platforms. The company is positioning its LineaDNA and LineaIVT platforms as solutions for critical manufacturing challenges in the rapidly expanding mRNA therapeutics and cell therapy sectors.
The presentation at the mRNA Process Development conference focuses on Applied DNA's synthetic DNA platform for optimizing mRNA production, accompanied by their IVT Discovery Kit offering. This demonstrates the company's commitment to addressing manufacturing bottlenecks in the mRNA space – a crucial consideration as mRNA therapeutics and vaccines continue gaining commercial traction following COVID-19 vaccine successes.
More notably, the CAR-TCR Summit presentation reveals the company's progression to Phase I clinical trials for CD123-specific CAR-T cells produced using their LineaDNA-based piggyBac transposon system for acute myeloid leukemia (AML) patients. This represents significant advancement beyond preclinical research and into human testing for their platform technology in cell therapy applications. The collaboration with the Institute of Hematology and Blood Transfusion in Prague suggests Applied DNA is leveraging strategic partnerships to advance clinical development.
The CD123 target is particularly relevant in AML treatment strategies, as this cell surface receptor is overexpressed in AML blasts and leukemic stem cells. Achieving Phase I trial status indicates the preclinical safety and efficacy data were sufficient to gain regulatory approval for human testing – a substantial milestone for the company's cell therapy platform.
These developments position Applied DNA as a technology enabler across two rapidly evolving therapeutic modalities: mRNA medicines and cell therapies. The company appears to be executing a strategy to provide critical manufacturing technologies that could potentially accelerate and improve production efficiency in these highly competitive fields.
STONY BROOK, NY / ACCESS Newswire / September 23, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a biotechnology company focused on providing nucleic acid production solutions for the biopharmaceutical and diagnostics industries, announced that members of its business development and technical teams will be in attendance at upcoming industry conferences and present posters that underscore the Company's flexible nucleic acid production solutions designed to meet critical unmet needs for the manufacture of advanced biotherapeutics:
4th Annual mRNA Process Development and CMC Summit (Boston, September 23-25)
Title: Fast-tracking mRNA Medicines: a synthetic DNA platform to optimize mRNA production
Authors: Atsuko Sangria1, Aaron Chung2, and Yuhua Sun2
Poster session date/time: Wednesday, September 24, at 3:10 p.m. Eastern
Poster: link
Also at the mRNA conference, Applied DNA will feature its IVT Discovery Kit, a powerful platform for evaluating and optimizing in vitro transcription (IVT). Meet our teams and discover for yourself how the Company's advanced solutions enable rapid, high-efficiency mRNA production, or request a Kit here.
10th Annual CAR-TCR Summit (Boston, September 23-26)
Title: CD123-specific CAR-T Cells Produced by Synthetic LineaDNA™-based piggyBac Transposon System - Initiation of Phase I Clinical Trial in Patients with AML
Authors: Jan Vydra3, Martin Mucha3, Iva Kaštánková3, Martin Štach3, Petr Lesný3, Finly Philip2,
Clay Shorrock2, Brian Viscount2, and Pavel Otáhal3Poster session date/time: Tuesday, September 23, at 6:30 p.m. Eastern
Poster: link
Footnotes:
1Research partner
2LineaRx, an Applied DNA Sciences company
3Institute of Hematology and Blood Transfusion, Prague, Czechia
About LineaDNA™ and LineaIVT™ Platforms
The LineaDNA platform is a proprietary, cell-free DNA production system that uses a large-scale polymerase chain reaction (PCR) process. This technology allows for the rapid and efficient production of high-fidelity synthetic DNA without the use of living cells. The resulting DNA can be used in the manufacturing of various biotherapeutics, serve as the starting material for mRNA therapeutics and vaccines, and as a critical component of IVDs.
The LineaIVT platform is an integrated system that combines the Company's LineaDNA and LineaRNAP technologies, the latter a next-generation RNAP engineered with a patented DNA-binding domain that Applied DNA believes results in high mRNA yields and reduced double-stranded RNA (dsRNA) contamination, a common problematic byproduct produced during mRNA production. This innovative platform simplifies the mRNA production workflow, resulting in a streamlined production process with fewer impurities than traditional methods.
About Applied DNA Sciences
Applied DNA Sciences is a biotechnology company focused on providing nucleic acid production solutions for the biopharmaceutical and diagnostics industries. Through its majority-owned subsidiary, LineaRx, Inc., the Company is commercializing its LineaDNA™, LineaRNAP™, and LineaIVT™ platforms to enable the manufacture of next-generation nucleic acid-based therapies.
Forward Looking Statements
The statements made by Applied DNA in this press release may be "forward-looking" in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Applied DNA's future plans, projections, strategies, and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. These forward-looking statements are based largely on the Company's expectations and projections about future events and future trends affecting our business and are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, including statements regarding its goal to position the Company for long-term growth and value creation and the potential to achieve that goal, including the future success of its LineaDNA, LineaRNAP and LineaIVT technologies. Actual results could differ materially from those projected due to its history of net losses, limited financial resources, unknown future ability to remain compliant with all Nasdaq listing standards, unknown future demand for its biotherapeutics products and services, the unknown amount of revenues and profits that will result from its technologies, the fact that there has never been therapeutic clinical trial material and/or a commercial drug product produced utilizing its technologies, as well as various other factors detailed from time to time in Applied DNA's SEC reports and filings, including its Annual Report on Form 10-K filed on December 17, 2024, Forms 10-Q filed on February 13, 2025, May 15, 2025, and August 14, 2025, and other reports it files with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.
Visit adnas.com for more information. Follow us on X and LinkedIn. Join our mailing list.
Investor Relations contact: Sanjay M. Hurry, 917-733-5573, sanjay.hurry@adnas.com
Web: www.adnas.com
X: APDN
SOURCE: Applied DNA Sciences, Inc.
View the original press release on ACCESS Newswire
FAQ
When and where will Applied DNA Sciences present at the mRNA Process Development Summit?
What will Applied DNA Sciences (APDN) present at the CAR-TCR Summit 2025?
What products will Applied DNA showcase at the mRNA conference?
Who are the authors of Applied DNA's CAR-T presentation?
